Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma
-
Published:2023-06
Issue:3
Volume:62
Page:103649
-
ISSN:1473-0502
-
Container-title:Transfusion and Apheresis Science
-
language:en
-
Short-container-title:Transfusion and Apheresis Science
Author:
Sawazaki AikoORCID,
Sugimori Chiharu,
Yamaguchi Masaki,
Nakao Shinji
Reference44 articles.
1. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma;Attal;N Engl J Med,2017
2. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
3. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials;Koreth;Biol Blood Marrow Transpl,2007
4. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival;Lahuerta;J Clin Oncol,2008
5. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial;Moreau;Blood,2011